title: A review of cost-effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis.
abstract: Rheumatoid arthritis (RA) is an autoimmune chronic disease which is associated with an increasing disability in patients and high socioeconomic burden. Given the large number of economic evaluations considered by national health technology assessments (HTAs), this review attempts to clarify whether results from biologic disease-modifying antirheumatic drugs (DMARDs) economic evaluations form the basis of official recommendation by national HTA agencies in Australia, Canada, Scotland and England. The results show that evidence of cost-effectiveness was not equally perceived by decision makers and did not have equal weightage in defining the official listing of biologic DMARDs for the treatment of RA. As it has been demonstrated in previous studies, major barriers exist for the integration of cost-effectiveness and cost-utility results with national HTA activity. In fact, as shown in this review, even when such analysis are available, cost-minimization and comparative effectiveness studies seemed to be preferred by some HTA agencies as tools to inform allocation of healthcare resources.
authors: IMS RWE Solutions & HEOR, Milan, Italy. siannazzo@it.imshealth.com
authors: Sergio
authors: S
authors: Iannazzo
authors: Maria
authors: M
authors: De Francesco
authors: David
authors: D
authors: Gomez-Ulloa
authors: Maurizio
authors: M
authors: Benucci
mesh_terms: D018501:Antirheumatic Agents / Q000191:economics* / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D019317:Evidence-Based Medicine; D019983:Guideline Adherence; D015276:Health Care Rationing / Q000191:economics; D006291:Health Policy / Q000191:economics*; D006801:Humans; D018803:Models, Economic; D011050:Policy Making; D017410:Practice Guidelines as Topic; D019057:Quality-Adjusted Life Years; D013673:Technology Assessment, Biomedical / Q000191:economics* / Q000592:standards; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents